Effects of bioactive lipids and lipoproteins on bone

Trends in Endocrinology and Metabolism

Volumn 25, Issue 2, 2014, Pages 53-59

  Tintut, Yin ^a   Demer, Linda L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ARYLDIALKYLPHOSPHATASE 1; BONE MORPHOGENETIC PROTEIN; CHOLESTEROL; FAT; HIGH DENSITY LIPOPROTEIN; HYDROXYL RADICAL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHOLIPID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOMATOMEDIN; SUPEROXIDE; THIOL; TRIACYLGLYCEROL;

ATHEROGENESIS; BIOLOGICAL ACTIVITY; BONE CELL; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL STRESS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID OXIDATION; LIPID STORAGE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANABOLIC AGENTS; ANIMALS; ATHEROSCLEROSIS; BONE AND BONES; BONE DENSITY; CELL DIFFERENTIATION; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; LIPIDS; LIPOPROTEINS; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 84892951063     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.10.001     Document Type: Review

References (88)

1. Annema W., Tietge U.J. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr. Metab. (Lond.) 2012, 9:25.
2. Di Angelantonio E., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
3. Lewington S., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
4. Navab M., et al. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J. Lipid Res. 2012, 53:437-445.
5. Navab M., et al. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2553-2560.
6. Huang Y., et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest. 2013, 123:3815-3828.
7. Bhattacharyya T., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
8. Ng D.S., et al. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc. Pathol. 2008, 17:226-232.
9. Gong M., et al. Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation. Biochem. Biophys. Res. Commun. 2009, 379:1001-1004.
10. Shih D.M., et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ. Res. 2007, 100:1200-1207.
11. Borja M.S., et al. HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS ONE 2013, 8:e71541.
12. Alexander E.T., et al. Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:320-327.
13. Wen D., et al. Lipids and collagen matrix restrict the hydraulic permeability within the porous compartment of adult cortical bone. Ann. Biomed. Eng. 2010, 38:558-569.
14. Irving J.T. Calcification of the organic matrix of enamel. Arch. Oral Biol. 1963, 8:773-774.
15. Reid D.G., et al. Lipids in biocalcification: contrasts and similarities between intimal and medial vascular calcification and bone by NMR. J. Lipid Res. 2012, 53:1569-1575.
16. Fang Y., et al. Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. J. Bone Miner. Metab. 2012, 30:60-68.
17. Niemeier A., et al. The role of apolipoprotein E in bone metabolism. Bone 2012, 50:518-524.
18. Jiang G., et al. Coronary heart disease mortality in China: age, gender, and urban-rural gaps during epidemiological transition. Rev. Panam. Salud Publica 2012, 31:317-324.
19. Tamaki J., et al. Low bone mass is associated with carotid atherosclerosis in postmenopausal women: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos. Int. 2009, 20:53-60.
20. Hmamouchi I., et al. Low bone mineral density is related to atherosclerosis in postmenopausal Moroccan women. BMC Public Health 2009, 9:388.
21. Naves M., et al. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos. Int. 2008, 19:1161-1166.
22. Szulc P., et al. Calcifications in the abdominal aorta predict fractures in men: MINOS study. J. Bone Miner. Res. 2008, 23:95-102.
23. Tanko L.B., et al. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif. Tissue Int. 2003, 73:15-20.
24. Barengolts E.I., et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif. Tissue Int. 1998, 62:209-213.
25. Collins T.C., et al. Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men. Circulation 2009, 119:2305-2312.
26. Kim Y.H., et al. Low bone mineral density is associated with dyslipidemia in South Korean men: the 2008-2010 Korean National Health and Nutrition Examination Survey. Endocr. J. 2013, 10.1507/endocrj.EJ13-0224.
27. Saghafi H., et al. Relationship between lipid profile and bone turnover in pre and postmenopausal women. Iran. J. Publ. Health (Supplementary issue on Osteoporosis and Bone Turnover) 2008, 1:23-29.
28. Makovey J., et al. Association between serum cholesterol and bone mineral density. Bone 2009, 44:208-213.
29. Brownbill R.A., Ilich J.Z. Lipid profile and bone paradox: higher serum lipids are associated with higher bone mineral density in postmenopausal women. J. Womens Health (Larchmt) 2006, 15:261-270.
30. Jeong I.K., et al. Lipid profiles and bone mineral density in pre- and postmenopausal women in Korea. Calcif. Tissue Int. 2010, 87:507-512.
31. Nozue T., et al. Cholesterol-years score is associated with development of senile degenerative aortic stenosis in heterozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 2006, 13:323-328.
32. Lim H.Y., et al. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. Am. J. Pathol. 2009, 175:1328-1337.
33. Awan Z., et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2008, 28:777-785.
34. Rowlan J.S., et al. Atherosclerosis susceptibility loci identified in an extremely atherosclerosis-resistant mouse strain. J. Am. Heart Assoc. 2013, 2:e000260.
35. Desai M.S., et al. Atherogenic diet-induced hepatitis is partially dependent on murine TLR4. J. Leukoc. Biol. 2008, 83:1336-1344.
36. Graham L.S., et al. Bone density and hyperlipidemia: the T-lymphocyte connection. J. Bone Miner. Res. 2010, 25:2460-2469.
37. Hirasawa H., et al. ApoE gene deficiency enhances the reduction of bone formation induced by a high-fat diet through the stimulation of p53-mediated apoptosis in osteoblastic cells. J. Bone Miner. Res. 2007, 22:1020-1030.
38. Parhami F., et al. Atherogenic high-fat diet reduces bone mineralization in mice. J. Bone Miner. Res. 2001, 16:182-188.
39. Pirih F., et al. Adverse effects of hyperlipidemia on bone regeneration and strength. J. Bone Miner. Res. 2012, 27:309-318.
40. Ionova-Martin S.S., et al. Reduced size-independent mechanical properties of cortical bone in high-fat diet-induced obesity. Bone 2010, 46:217-225.
41. Soares E.A., et al. Effect of hyperlipidemia on femoral biomechanics and morphology in low-density lipoprotein receptor gene knockout mice. J. Bone Miner. Metab. 2012, 30:419-425.
42. Brown M.D., et al. Lipid retention in the arterial wall of two mouse strains with different atherosclerosis susceptibility. J. Lipid Res. 2004, 45:1155-1161.
43. Shi W., et al. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation 2000, 102:75-81.
44. Schilling A.F., et al. Increased bone formation in mice lacking apolipoprotein E. J. Bone Miner. Res. 2005, 20:274-282.
45. Smith W.L., Murphy R.C. Oxidized lipids formed non-enzymatically by reactive oxygen species. J. Biol. Chem. 2008, 283:15513-15514.
46. Gleissner C.A., et al. Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis. Hypertension 2007, 50:276-283.
47. Gutierrez L.L., et al. Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins. Biochem. Pharmacol. 2008, 75:2245-2262.
48. Spanbroek R., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1238-1243.
49. Aoki T., Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol. Sci. 2012, 33:304-311.
50. Kadl A., et al. Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Radic. Biol. Med. 2011, 51:1903-1909.
51. Kawai K., et al. Fat necrosis of osteocytes as a causative factor in idiopathic osteonecrosis in heritable hyperlipemic rabbits. Clin. Orthop. Relat. Res. 1980, 153:273-282.
52. Watanabe Y., et al. Histopathology of femoral head osteonecrosis in rheumatoid arthritis: the relationship between steroid therapy and lipid degeneration in the osteocyte. Rheumatol. Int. 1989, 9:25-31.
53. Tintut Y., et al. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler. Thromb. Vasc. Biol. 2004, 24:e6-e10.
54. Maurel D.B., et al. Osteocyte apoptosis and lipid infiltration as mechanisms of alcohol-induced bone loss. Alcohol Alcohol. 2012, 47:413-422.
55. Gordon S. Macrophage heterogeneity and tissue lipids. J. Clin. Invest. 2007, 117:89-93.
56. Wuthier R.E. Lipids of matrix vesicles. Fed. Proc. 1976, 35:117-121.
57. Dirksen T.R., Marinetti G.V. Lipids of bovine enamel and dentin and human bone. Calcif. Tissue Res. 1970, 6:1-10.
58. Brodeur M.R., et al. Influence of oxidized low-density lipoproteins (LDL) on the viability of osteoblastic cells. Free Radic. Biol. Med. 2008, 44:506-517.
59. Almeida M., et al. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J. Biol. Chem. 2009, 284:27438-27448.
60. Maziere C., et al. Oxidized low density lipoprotein inhibits phosphate signaling and phosphate-induced mineralization in osteoblasts. Involvement of oxidative stress. Biochim. Biophys. Acta 2010, 1802:1013-1019.
61. Li X., et al. Mechanism of hyperlipidemia-induced parathyroid hormone (PTH) resistance: a role of PTH receptor and reactive oxygen species in preosteoblasts. J. Cell. Biochem. 2013, 24038594.
62. Matsuzawa N., et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007, 46:1392-1403.
63. Parhami F., et al. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J. Bone Miner. Res. 1999, 14:2067-2078.
64. Arai M., et al. Effects of reactive oxygen species (ROS) on antioxidant system and osteoblastic differentiation in MC3T3-E1 cells. IUBMB Life 2007, 59:27-33.
65. Chuang C.C., et al. Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling. Endocrinology 2007, 148:4267-4275.
66. Hernandez J.L., et al. Metabolic syndrome, fractures and gender. Maturitas 2011, 68:217-223.
67. Tintut Y., et al. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J. Biol. Chem. 2002, 277:14221-14226.
68. Tseng W., et al. Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids. J. Lipid Res. 2010, 51:1010-1016.
69. Graham L.S., et al. Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin. Immunol. 2009, 133:265-275.
70. Bonewald L.F. The amazing osteocyte. J. Bone Miner. Res. 2011, 26:229-238.
71. Tatsumi S., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007, 5:464-475.
72. Xiong J., et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 2011, 17:1235-1241.
73. Harada S., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
74. Cipriani C., et al. Safety of osteoanabolic therapy: a decade of experience. J. Bone Miner. Res. 2012, 27:2419-2428.
75. Chen P., et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J. Bone Miner. Res. 2007, 22:1173-1180.
76. Wang Y.H., et al. Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E594-E603.
77. Wang Y., et al. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J. Bone Miner. Res. 2007, 22:1329-1337.
78. Huang M.S., et al. Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts. J. Biol. Chem. 2007, 282:21237-21243.
79. Huang M.S., et al. Hyperlipidemia impairs osteoanabolic effects of PTH. J. Bone Miner. Res. 2008, 23:1672-1679.
80. Lu J., et al. Role of paraoxonase-1 in bone anabolic effects of parathyroid hormone in hyperlipidemic mice. Biochem. Biophys. Res. Commun. 2013, 431:19-24.
81. Sage A.P., et al. Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids. J. Bone Miner. Res. 2011, 26:1197-1206.
82. Jeon Y.K., et al. The anabolic effect of teriparatide is undermined by low levels of high-density lipoprotein cholesterol. Calcif. Tissue Int. 2013, 10.1007/s00223-013-9772-0.
83. Parhami F., et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 1997, 17:680-687.
84. Chu C.S., et al. Electronegative low-density lipoprotein increases c-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS ONE 2013, 8:e70533.
85. Collot-Teixeira S., et al. CD36 and macrophages in atherosclerosis. Cardiovasc. Res. 2007, 75:468-477.
86. Zhang F., et al. Lectin-like oxidized LDL receptor-1 expresses in mouse bone marrow-derived mesenchymal stem cells and stimulates their proliferation. Exp. Cell Res. 2013, 319:1054-1059.
87. Matsumoto C., et al. Toll-like receptor 2 heterodimers, TLR2/6 and TLR2/1 induce prostaglandin E production by osteoblasts, osteoclast formation and inflammatory periodontitis. Biochem. Biophys. Res. Commun. 2012, 428:110-115.
88. Kulkarni R.N., et al. Mechanical loading prevents the stimulating effect of IL-1beta on osteocyte-modulated osteoclastogenesis. Biochem. Biophys. Res. Commun. 2012, 420:11-16.